MDMA trials for use in anxiety treatment
MDMA trials for use in anxiety treatment is officially a thing over at the Drug Enforcement Administration in the United States.
The trial is intended to determine the efficacy and safety of MDMA in treating anxiety in patients who have life threatening illnesses.
This trial is indicative of how the drug which is also known as molly or ecstasy could now face a future where it is no longer viewed as a drug with no medical purpose.
During the peak of the ‘war on drugs’ in 1985 the DEA categorised MDMA in Schedule I under the Controlled Substances Act. The federal government considers Schedule I drugs to be among the most dangerous’ with no known medical benefits and the potential for “severe psychological or physical dependence.”
Only now, they’re changing their tune and depending on the outcome of these clinical MDMA trials, the image of the drug could change forever.
In the years since, members of the medical community have continued to argue that MDMA doesn’t belong in Schedule I. Other relevant studies, also approved by the DEA, have found that the drug could be an effective treatment for post-traumatic stress disorder when administered under proper supervision. Well what do you know.
The latest study is being sponsored by the Multidisciplinary Association for Psychedelic Studies, a non-profit organization that funds research on beneficial uses of psychedelics and marijuana. MAPS sees the DEA’s approval as a sign of change.
“The smooth process of regulatory approval for this study indicates that stigma is no longer standing in the way of regulatory approval for research into the therapeutic uses of MDMA and other psychedelics. Now, the main challenge has become finding the funding necessary to complete the research. As these studies move forward, we’ll start seeing support for psychedelic research as an opportunity, rather than a risk.”Brad Burge, communications director for MAPS
MAPS said that eighteen patients diagnosed with life-threatening illnesses will undergo MDMA assisted psychotherapy sessions under the supervision of Dr. Philip Wolfson, the study’s principal investigator, at an office in Marin, California.
The year-and-a-half MDMA trials study will test the drug’s potential for treating anxiety and stress disorders related to the end of life.
Source: Huffington Post